Follicular lymphoma: trials for referral
200 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
200 trials shown
Phase 3288 sites
RecruitingUnited States
NCT06337318
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 296 sites
RecruitingUnited States
NCT04803201
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Pre-treatment window Registry sentence: “No prior systemic therapy for lymphoma (excluding corticosteroids)”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 113 sites
RecruitingAustralia, Canada, Spain, Italy, United States
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07783594
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “Have no prior systemic treatment for lymphoma”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 128 sites
RecruitingAustralia, Spain, France, Italy, Poland, United States
NCT07691606
A Study of ARC-02 in B-cell NHL
Taiho Oncology, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT04404088
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “Have had no prior systemic treatment for lymphoma”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT07691450
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
City of Hope Medical Center
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase6 sites
RecruitingUnited States
NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/261 sites
RecruitingArgentina, Australia, Brazil, Canada, Chile, China
NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT01137643
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingAustralia, Israel
NCT07249905
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 2104 sites
RecruitingUnited States
NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 2/339 sites
RecruitingArgentina, Australia, Chile, China, Germany, Spain
NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5.”
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingUnited States
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06108232
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “Have no prior systemic treatment for lymphoma”
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 37 sites
RecruitingUnited States
NCT07029217
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Memorial Sloan Kettering Cancer Center
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
New York Medical College
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 26 sites
RecruitingDenmark
2025-521205-41-00
A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma
Aalborg University Hospital
Registry updated 23 Oct 2026
Registry record: EU CTISPhase 3217 sites
RecruitingAustralia, Belgium, Brazil, Canada, China, Czechia
NCT06549595
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 1/229 sites
RecruitingChina
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 27 sites
RecruitingUnited States
NCT06834373
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07883941
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
GUSTAVO SALGUERO
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT03190928
Clonal Evolution in Follicular Lymphoma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Any prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); patients who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other malignancies are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL”
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07638982
Axatilimab + CAR-T for High-Risk Lymphoma
Northside Hospital, Inc.
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 22 sites
Not yet recruitingUnited States
NCT07875413
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
AbelZeta Inc.
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 295 sites
RecruitingUnited States
NCT05633615
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 187 sites
RecruitingBulgaria, China, Spain, Japan, South Korea, Poland
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 16 sites
RecruitingChina, United States
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govNo phase4 sites
RecruitingCzechia, Greece, Israel, Lithuania
NCT05735704
Early Detection and Screening of Hematological Malignancies - SANGUINE
JaxBio Ltd
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States103 open trials
- China52 open trials
- Italy25 open trials
- France24 open trials
- Spain20 open trials
- Germany19 open trials
- Australia18 open trials
- United Kingdom15 open trials
- South Korea15 open trials
- Poland14 open trials
- Canada11 open trials
- Israel8 open trials
- Brazil8 open trials
- Taiwan8 open trials
- Japan8 open trials
- Denmark7 open trials
- Greece6 open trials
- Czechia5 open trials
- Belgium5 open trials
- Austria5 open trials
- Chile4 open trials
- Sweden4 open trials
- Argentina3 open trials
- India3 open trials
- Switzerland3 open trials
- Moldova3 open trials
- Netherlands3 open trials
- Finland3 open trials
- Hong Kong SAR China2 open trials
- Hungary2 open trials
- Thailand2 open trials
- Puerto Rico2 open trials
- Bulgaria2 open trials
- Lithuania2 open trials
- Georgia2 open trials
- Romania2 open trials
- Ukraine2 open trials
- Norway2 open trials
- Portugal2 open trials
- Russia1 open trials
- Malaysia1 open trials
- Iceland1 open trials
- Croatia1 open trials
- United Arab Emirates1 open trials
- Saudi Arabia1 open trials
- Mexico1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
0 trials · 27 publications · ROR
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
0 trials · 19 publications · ROR
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
9 trials · 35 publications · ROR
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
12 trials · 24 publications · ROR
Cancer Research UK Manchester Centre
Greater Manchester, United Kingdom
0 trials · 31 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 49 publications · ROR
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Barcelona, Spain
0 trials · 24 publications · ROR
Groupe de Recherche sur les formes Injectables et les Technologies Associées
Lille, France
0 trials · 22 publications · ROR
Institut universitaire du cancer de Toulouse Oncopole
Toulouse, France
0 trials · 40 publications · ROR
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
2 trials · 23 publications · ROR
Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg, Australia
1 trials · 20 publications · ROR
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, United States
0 trials · 19 publications · ROR
The Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
0 trials · 23 publications · ROR
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, United States
0 trials · 34 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
7 trials · 189 publications · ROR
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
2 trials · 46 publications · ROR
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
Vercelli, Italy
0 trials · 28 publications · ROR
University College London Hospitals NHS Foundation Trust
London, United Kingdom
1 trials · 19 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
1 trials · 26 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
No registry change in the last 7 days.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 4 Sept 2026
Completed27 participants
NCT05359211
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Phase 1/2Ended 28 Aug 2026
Completed36 participants
NCT03015896
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 1Ended 31 Mar 2026
Completed16 participants
NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Phase 1Ended 13 Feb 2026
Completed25 participants
NCT00641381
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 3Ended 3 Feb 2026
Completed330 participants
NCT03570892
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Phase 2Ended 5 Jan 2026
Phase 3Ended 31 Dec 2025
Completed571 participants
NCT00006721
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
- Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
Phase 1/2Ended 23 Dec 2025
Completed803 participants
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. · Cancer chemotherapy and pharmacology, 2026
Phase 1Ended 24 Nov 2025
Completed35 participants
NCT02568553
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 2Ended 31 Oct 2025
Completed17 participants
NCT03210662
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2Ended 30 Oct 2025
Completed40 participants
NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase 1/2Ended 27 Oct 2025
Completed161 participants
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase 1Ended 6 Oct 2025
Completed16 participants
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Phase 2Ended 2 Sept 2025
Completed135 participants
NCT01286272
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Phase 1Ended 21 Aug 2025
Completed200 participants
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Phase 1Ended 1 Aug 2025
Completed50 participants
NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1/2Ended 30 Jun 2025
Completed55 participants
NCT04172246
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Phase 3Ended 9 Jun 2025
Completed445 participants
NCT02947347
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Phase 2Ended 28 May 2025
Completed98 participants
NCT03568461
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Phase 2Ended 2 Apr 2025
Completed42 participants
NCT05169658
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
No phaseEnded 27 Mar 2025
Completed151 participants
NCT04618081
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
Phase 2Ended 24 Mar 2025
Completed78 participants
NCT02988466
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 1Ended 12 Mar 2025
Completed17 participants
NCT05075603
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Phase 1Ended 7 Mar 2025
Completed52 participants
NCT04088890
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Phase 1Ended 25 Feb 2025
Completed16 participants
2024-516907-18-00
A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Participants
Phase 1Ended 21 Feb 2025
Completed8 participants
NCT04578600
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1Ended 28 Jan 2025
Completed50 participants
NCT03939026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
No phaseEnded 31 Dec 2024
Phase 2Ended 27 Dec 2024
Completed217 participants
NCT03332017
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Phase 1/2Ended 20 Dec 2024
Completed169 participants
NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 2Ended 20 Dec 2024
Completed159 participants
NCT03105336
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Phase 2Ended 19 Dec 2024
Completed135 participants
NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
No phaseEnded 1 Dec 2024
Phase 2Ended 30 Nov 2024
Completed42 participants
NCT05467943
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
No phaseEnded 17 Nov 2024
Completed102 participants
NCT06782854
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
No phaseEnded 14 Nov 2024
Completed35 participants
NCT05784415
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
Phase 1Ended 11 Nov 2024
Completed110 participants
NCT02635672
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Phase 1Ended 11 Nov 2024
Completed6 participants
2023-508371-36-00
A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497
Phase 1/2Ended 29 Oct 2024
Completed55 participants
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1Ended 29 Oct 2024
Completed134 participants
NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Phase 2Ended 25 Oct 2024
Completed30 participants
NCT05008055
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1Ended 10 Oct 2024
Completed14 participants
NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1/2Ended 4 Oct 2024
No phaseEnded 1 Oct 2024
Completed39 participants
NCT04833504
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Phase 2Ended 29 Sept 2024
Completed17 participants
NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Phase 3Ended 17 Sept 2024
Phase 1/2Ended 28 Aug 2024
Completed97 participants
NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Phase 3Ended 2 Jul 2024
Completed211 participants
NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Phase 2Ended 26 Jun 2024
Completed96 participants
NCT02871219
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Phase 1Ended 24 Jun 2024
Phase 1Ended 20 Jun 2024
Completed11 participants
NCT04599634
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 2Ended 7 Jun 2024
Completed126 participants
NCT03126019
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Phase 2Ended 28 May 2024
Completed22 participants
NCT04432506
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
No phaseEnded 28 May 2024
Completed10 participants
NCT00547196
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Phase 1Ended 16 May 2024
Completed387 participants
NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Phase 1Ended 13 May 2024
Completed36 participants
2023-507497-40-00
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1Ended 6 May 2024
Completed18 participants
NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 3Ended 30 Apr 2024
Completed1030 participants
NCT01476787
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Phase 1Ended 30 Apr 2024
Completed154 participants
NCT02924402
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 3Ended 30 Apr 2024
Not medical advice. fetched 4 Nov 2026